Project Grant R01DA066989
Award Date 8/15/26
Completion Date 6/30/31
Dollars Obligated $461K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
- The National Institutes of Health Office of the Director awarded the University of California, San Diego $480,000 on August 15, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct research on metabolic-epigenetic mechanisms of neurotoxicity following acute fentanyl exposure. The project, which runs through June 30, 2031, investigates how ultra-potent synthetic opioids such as fentanyl cause delayed neurological consequences in overdose survivors despite effective opioid...
- The National Institute on Drug Abuse awarded the University of California, San Diego $138,522 under the Drug Use and Addiction Research Programs (CFDA 93.279) on January 21, 2026. The award funds research evaluating the multiscale effects of fentanyl-induced dependence and abstinence within the mouse basolateral amygdala. The research employs virally-mediated strategies, nuclear labeling, and single-nucleus RNA sequencing to assess how fentanyl dependence and abstinence differentially affect...
- The National Institute on Drug Abuse awarded Emory University $1,095,500 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate fentanyl's impact on HIV/HBV co-infection dynamics and identify targetable metabolic pathways for therapeutic intervention. The project, titled "The Metabolic Crossroads: Decoding Fentanyl's Impact on HIV/HBV Co-Infection for Targeted Interventions," will characterize how fentanyl exposure alters viral replication...
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $673,724 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to study how opioid exposure modifies nucleus accumbens microcircuits and to develop strategies to reverse or prevent maladaptive opioid-evoked neural plasticity. The research focuses on low-threshold spiking interneurons (LTSIs) in the nucleus accumbens, which are gatekeepers of nucleus accumbens output and regulate...
- The National Institute on Drug Abuse awarded the University of Miami $516,914 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on HIV infection of brain pericytes and the molecular synergy between HIV and methamphetamine use. The research focuses on understanding how methamphetamine influences HIV latency and reservoir formation in brain pericytes, which the investigative team identified as susceptible to productive HIV infection and capable of...
- The National Institute on Drug Abuse awarded the University of Miami $164,190 on August 19, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on dopamine dysregulation and oxidative stress in HIV and methamphetamine-induced cognitive impairment. The research will evaluate the effect of quetiapine, an atypical antipsychotic, on neurocognitive deficits and depressive symptoms in mice infected with ECOHIV (a murine-tropic HIV) and/or receiving...
- The National Institute on Drug Abuse awarded The Trustees of The University of Pennsylvania $708,040 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on distinct amygdalar neural circuits involved in pain and opioid dependence. The award funds investigation of how chronic opioid exposure alters specific brain circuits that mediate pain and threat responses, using a mouse model of fentanyl dependence compatible with postoperative pain....
- The National Institutes of Health Office of the Director awarded the Regents of the University of Minnesota $361,562 on June 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to develop long-acting nanoparticle formulations for treating synthetic opioid overdose. The project centers on development and testing of antagonist nanoparticles (naloxone, nalmefene, and naltrexone), mixed agonist-antagonist nanoparticles (buprenorphine, nalbuphine, and butorphanol), and an agonist...
- The National Institute on Drug Abuse awarded Trustees of Tufts College (doing business as Tufts University School of Medicine) $618,725 on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate fentanyl overdose-induced anhedonia and relapse risk. The research examines whether fentanyl overdose intensifies addiction cycles through alterations in reward processing. The project tests three specific aims: whether fentanyl overdose leads to development or...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,387,755 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate mitochondrial oxidative phosphorylation dysregulation in HIV-associated neurocognitive disorder and opioid use disorder, with NAD+ treatment as a potential therapeutic strategy. The research establishes a three-dimensional human assembloid model composed of iPSC-derived neurons, astrocytes, microglia, and...